

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
13180.18

In Re Application Of: ROULEAU et al.

JUN 1 2 2001

Serial No.  
09/718,355

Filing Date  
11/24/2000

Examiner

Group Art Unit  
1645

Title:

**LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS THEREOF AND METHOD USING SAME  
TO ASSESS, DIAGNOSE, PROGNOSIS OR TREAT EPILEPSY**

**RECEIVED**

Address to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

JUN 1 3 2001  
TECH CENTER 1600/2900

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

**OR**

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.

13180.18

In Re Application Of: ROULEAU et al.

Serial No.

09/718,355

Filing Date

11/24/2000

Examiner

Group Art Unit

1645

Title:

**LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS THEREOF AND METHOD USING SAME  
TO ASSESS, DIAGNOSE, PROGNOSIS OR TREAT EPILEPSY**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 07-1742 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

on \_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**\*This certificate may only be used if paying by deposit account.**

\_\_\_\_\_  
Signature

**Alain M. LECLERC, Reg. No. 37036**

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on \_\_\_\_\_ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

\_\_\_\_\_  
Signature of Person Mailing Correspondence

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Correspondence

Dated: **June 11, 2001**

CC:

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
13180.18

In Re Application Of: ROULEAU et al.



Serial No.  
09/718,355

Filing Date  
11/24/2000

Examiner

Group Art Unit  
1645

Title:

**LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS THEREOF AND METHOD USING SAME  
TO ASSESS, DIAGNOSE, PROGNOSIS OR TREAT EPILEPSY**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 07-1742 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

\_\_\_\_\_) on \_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**\*This certificate may only be used if paying by deposit account.**

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on \_\_\_\_\_ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

\_\_\_\_\_  
Signature of Person Mailing Correspondence

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Correspondence

Dated: June 11, 2001


\_\_\_\_\_  
Signature

**Alain M. LECLERC, Reg. No. 37036**

CC:

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

CG/13180.18

Application Number

09/718,355

Applicant(s)

ROULEAU, Guy A.

Filing Date

November 24, 2000

Group Art Unit

1645

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,223,409		Ladner et al.			

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	Anderman, E. 1982, Genetic Basis of the Epilepsies, Raven Press, New York: 355-374.	✓
	2	Anderson et al. 1984, In Vitro 20(11): 856-8.	✓


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

CG/13180.18

Application Number

09/718,355

Applicant(s)

ROULEAU, Guy A.

Filing Date

November 24, 2000

Group Art Unit

1645

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

- |    |  |
|----|--|
| 3  | Annegers et al. 1982, Genetic Basis of the Epilepsies, Raven Press, New York: 151-9. ✓ |
| R  | Baker et al. 1995, Cell Prolif. 28: 1-15. ✓  |
| 5  | Barker et al. 1984, Neurosci. Lett. 47: 313-8. ✓                                       |
| b  | Bar-Sagi et al. 1985, J. Biol. Chem. 260(8): 4740-4. ✓                                 |
| 1  | Baunoch et al. 1992, Biotechniques 12(3): 412-7. ✓                                     |
| 6  | Berkovic et al. 1998, Ann. Neurol. 43: 435-45. ✓                                       |
| 9  | Biervert et al. 1998, Science 279: 403-6. ✓  |
| 10 | Bu et al. 1994, Genomics 21: 222-8. ✓  |
| 11 | Carell et al. 1994, Angew. Chem. Int. Ed. Engl. 33(20): 2061-63.                       |
| 12 | Charlier et al. 1998, Nat. Genet. 18(1): 53-5.   |
| 13 | Chevion et al. 1996, Cell Prolif. 29: 437-46.  |
| 14 | Chia et al. 1998, Exp. Cell Res. 244: 340-8.   |


EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)




Docket Number (Optional) <b>CG/13180.18</b>	Application Number <b>09/718,355</b>
Applicant(s) <b>ROULEAU, Guy A.</b>	
Filing Date <b>November 24, 2000</b>	Group Art Unit <b>1645</b>

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Cho et al. 1993, Science <u>261</u> : 1303-5. ✓
15	
	Clare et al. 2000, Drug Discov. Today <u>5</u> (11): 506-20. ✓
16	
	Commission on Classification and Terminology of the International League Against Epilepsy 1989, Epilepsia <u>30</u> (4): 389-99. ✓
17	
	Corey et al. 1991, Neurology <u>41</u> : 1433-6. ✓
18	
	Cull et al. 1992, Proc. Natl. Acad. Sci. USA <u>89</u> : 1865-9. ✓
19	
	Denyer et al. 1998, Drug Discovery Today <u>3</u> : 323-32. ✓
20	
	DeWitt et al. 1993, Proc. Natl. Acad. Sci. USA <u>90</u> : 6909-13. ✓
21	
	Elliott et al. 1999, Oncogene <u>18</u> : 3564-73. ✓
22	
	Elmslie et al. 1997, Hum. Mol. Genet. <u>6</u> (8): 1329-34. ✓
23	
	Engel et al. 1997, Epilepsy: A Comprehensive Textbook, Lippincott-Raven, Philadelphia: 1-7 (1). ✓
24	
	Erb et al. 1994, Proc. Natl. Acad. Sci. USA <u>91</u> : 11422-6. ✓
25	
	Escayg et al. 2000, Nat. Genet. <u>24</u> (4): 343-5.
26	
EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)  
CG/13180.18

Application Number  
09/718,355

Applicant(s)  
ROULEAU, Guy A.

Filing Date  
November 24, 2000


Group Art Unit  
1645

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
28	Fodor et al. 1993, Nature <u>364</u> : 553-6. ✓
28	Gallop et al. 1994, J. Med. Chem. <u>37</u> (9): 1233-51. ✓
29	Gonzalez et al. 1998, Cellular and Molecular Biology <u>44</u> (7): 1117-27. ✓
30	Gonzalez et al. 1999, Drug Discovery Today <u>4</u> (9): 431-9. ✓
31	Greenberg et al. 1988, Am. J. Med. Genet. <u>31</u> : 185-92. ✓
22	Guipponi et al. 1997, Hum. Mol. Genet. <u>6</u> : 473-7. ✓
31	Gyapay et al. 1994, Nat. Genet. <u>7</u> : 246-9. ✓
34	Hamill et al. 1981, Pflügers Archiv. <u>391</u> : 85-100. ✓
35	Hu et al. 1999, The Journal of Pharmacology and Experimental Therapeutics <u>290</u> (1): 28-37. ✓
36	Kawai et al. 1999, Oncogene <u>18</u> : 3471-80. ✓
37	Komada et al. 1999, Genes & Dev. <u>13</u> : 1475-85. ✓
38	Lam, K.S. 1997, Anti-Cancer Drug Design <u>12</u> : 145-67. ✓
EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

CG/13180.18

Application Number

09/718,355

Applicant(s)

ROULEAU, Guy A.

Filing Date

November 24, 2000

Group Art Unit

1645

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Lam et al. 1991, Nature (354): 82-84. ✓

Lathrop et al. 1984, Am. J. Genet., 36: 460-5. ✓

Lennox et al. 1960, Epilepsy and related disorders, Little Brown: 532-74. ✓

Leppert et al. 1989, Nature 337: 647-8. ✓

Lewis et al. 1993, Am. J. Hum. Genet. 53: 670-5. ✓

Liu, L. 1999, Cell. Signal. 11(5): 317-24.

McConnell et al. 1992, Science 257: 1906-12. ✓

McPhee et al. 1998, J. Biol. Chem. 273(2): 1121-9. ✓

Miyaji-Yamaguchi et al. 1999, Journal of Molecular Biology 290: 547-57.

Morvan et al. 1986, Nucleic Acids Research, 14(12): 5019-35. ✓

Muir et al. 2000, Cerebrovascular Diseases 10: 431-6. ✓

Nakashima et al. 1999, J. Bone Joint Surg. Am. 81(5): 603-15. ✓

EXAMINER


DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

CG/13180.18

Application Number

09/718,355

Applicant(s)

ROULEAU, Guy A.

Filing Date

November 24, 2000

Group Art Unit

1645

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Abstract, Title, Date, Pertinent Pages, Etc.)

Nielsen, P.E. 1999, Curr. Opin. Biotechnol. 10: 71-5.

51

Okuwaki et al. 1998, J. Biol. Chem. 273(51): 34511-8.

52

Ottman et al. 1989, Epilepsia 30(2): 157-61.

53

Ottman et al. 1995, Nat. Genet. 10: 56-60.

54

Ottman et al. 1997, Am. J. Hum. Genet. 60: 667-75.

55

Pugsley et al. 1998, Eur. J. Pharmacol. 342: 93-104.

56

Schroeder et al. 1998, Nature 396: 687-90.

57

Scott et al. 1990, Science 249: 386-90.

58

Silampää et al. 1991, Acta Neurol. Scand. 84: 523

59

Singh et al. 1998, Nat. Genet. 18(1): 25-9.

60

Sjolander et al. 1991, Anal. Chem. 63: 2338-45.

61

Steinlein et al. 1995, Nat. Genet. 11: 201-3.

62


EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

CG/13180.18

Application Number

09/718,355

Applicant(s)

ROULEAU, Guy A.

Filing Date

November 24, 2000

Group Art Unit

1645

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Szabo et al. 1995, Curr. Opin. Biol. Sci. 5: 699-705.

63

Tamaskovic et al. 1999, Biological Chemistry 380: 569-78.

64

Taylor et al. 1997, Adv. Pharmacol. 39: 47-98.

65

Wallace et al. 1998, Nature Genet. 19: 366-70.

66

Zuchermann et al. 1994, J. Med. Chem. 37(17): 2678-85.

67

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.